135 related articles for article (PubMed ID: 36852510)
1. L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression.
Wiedenhoefer R; Schmoeckel E; Grube M; Sulyok M; Pasternak I; Beschorner C; Greif K; Brucker S; Mayr D; Kommoss S; Fend F; Staebler A; Fischer AK
Am J Surg Pathol; 2023 May; 47(5):558-567. PubMed ID: 36852510
[TBL] [Abstract][Full Text] [Related]
2. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
[TBL] [Abstract][Full Text] [Related]
3. L1 (CAM) (CD171) in ovarian serous neoplasms.
Daponte A; Kostopoulou E; Kollia P; Papamichali R; Vanakara P; Hadjichristodoulou C; Nakou M; Samara S; Koukoulis G; Messinis IE
Eur J Gynaecol Oncol; 2008; 29(1):26-30. PubMed ID: 18386459
[TBL] [Abstract][Full Text] [Related]
4. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
Cheng A; Li M; Kanis MJ; Xu Y; Zhang Q; Cui B; Jiang J; Zhang Y; Yang X; Kong B
Gynecol Oncol; 2017 Jan; 144(1):215-222. PubMed ID: 27889016
[TBL] [Abstract][Full Text] [Related]
6. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
7. Mucinous borderline ovarian tumors with BRAF
Ohnishi K; Nakayama K; Ishikawa M; Ishibashi T; Yamashita H; Nakamura K; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Arch Gynecol Obstet; 2020 Aug; 302(2):487-495. PubMed ID: 32556513
[TBL] [Abstract][Full Text] [Related]
8. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
[TBL] [Abstract][Full Text] [Related]
9. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
10. Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
Dewilde K; Moerman P; Leunen K; Amant F; Neven P; Vergote I
Gynecol Obstet Invest; 2018; 83(1):65-69. PubMed ID: 28689208
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
12. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Lee KR; Scully RE
Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
[TBL] [Abstract][Full Text] [Related]
13. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; ; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; ; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ
Clin Cancer Res; 2022 Dec; 28(24):5383-5395. PubMed ID: 36222710
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma.
He X; Ying R; Jia L; Li Y; Li R
Gland Surg; 2023 Apr; 12(4):453-464. PubMed ID: 37200926
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years.
Sun L; Li N; Song Y; Wang G; Zhao Z; Wu L
Int J Gynecol Cancer; 2018 Nov; 28(9):1643-1649. PubMed ID: 30365456
[TBL] [Abstract][Full Text] [Related]
17. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
18. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review.
Beroukhim G; Ozgediz D; Cohen PJ; Hui P; Morotti R; Schwartz PE; Yang-Hartwich ; Vash-Margita A
J Pediatr Adolesc Gynecol; 2022 Jun; 35(3):359-367. PubMed ID: 34843973
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
20. A distinct molecular profile associated with mucinous epithelial ovarian cancer.
Heinzelmann-Schwarz VA; Gardiner-Garden M; Henshall SM; Scurry JP; Scolyer RA; Smith AN; Bali A; Vanden Bergh P; Baron-Hay S; Scott C; Fink D; Hacker NF; Sutherland RL; O'Brien PM
Br J Cancer; 2006 Mar; 94(6):904-13. PubMed ID: 16508639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
